# Study to Evaluate Safety and Efficacy of LifeLiver in Acute or Acute-on-Chronic Liver Failure Patients

> **NCT03882346** · PHASE2 · UNKNOWN · sponsor: **HLB Cell Co., Ltd.** · enrollment: 40 (estimated)

## Conditions studied

- Acute Liver Failure
- Acute-On-Chronic Liver Failure

## Interventions

- **COMBINATION_PRODUCT:** LifeLiver

## Key facts

- **NCT ID:** NCT03882346
- **Lead sponsor:** HLB Cell Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-03-29
- **Primary completion:** 2022-03
- **Final completion:** 2022-06
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2020-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03882346

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03882346, "Study to Evaluate Safety and Efficacy of LifeLiver in Acute or Acute-on-Chronic Liver Failure Patients". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03882346. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*